Also, everyone keeps leaving out the party that ESRX v-pak Rxs are not being reported per a contractual obligation. So the real Rx # so far is 180 + that ESRX #.
IMS is underreprting V-Pak Rx data:
Those watching the launch through weekly prescription data from IMS Health (NYSE:IMS) were stymied by IMS' announcement that some of the prescriptions were not being reported due to "a contractual condition between a supplier and the manufacturer," and thus are being underreported, according to RBC Capital Markets analyst Michael Yee. Yee noted that sales of Viekira's competitors, Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi, were continuing in line with expectations for the two weeks after the Viekira launch, and were on track to do at least $12 billion this year.
RPRX down 7% while market is up. Guess the scam is finally over
The stock market is broadly up today while RPRX is down 3.5%. Why are you pretending it's otherwise?
If RPRX was anything but a scam they would have had a big pharama partner a long time ago. And since you're clueless about the FDA and this testosterone replacement thing:
Men over 65, as well as younger men with diagnosed heart disease, were at least twice as likely to have non-fatal heart attacks in the 90 days after they were prescribed testosterone medication than were men of the same age and health status who did not get the hormone supplement, a study has found.
Any thoughts on the FDA investigating testosterone products for cardio issue DJW? Do you really think the FDA will approve a new testosterone drug will this investigation is taking place?
Perhaps you should double check when you read things. Before today's data their peak guidance was 10%. They now admit that could "prove conservative"
Do you really think the FDA will approve a new testosterone drug any time soon while they're investigating the current ones?
Agree except the current market expects GILD to take 90% share and ABBV 10%. I think it will be significantly higher than that 25%
I don't disagree with you and don't really know the advantage ABBV is gaining from announcing this publicly. After the data today, I do think it will be approved in 2014, howveer
Considering the strength of the data, it will most likely be approved in under 8 months. ABBV wouldn't have said it if they didn't mean it.
ABBV expects to submit it's NDA in April of this year. Since it is designated as Breakthrough Therapy the FDA will act on it in 8 months or less. April + 8 months = dec 14. No one is forcing the FDAs hand here, it is just a fact that they will have it approved in 2014.
if you guys really think IDIX has a chance to compete with GILD and now ABBV/ENTA after their incredible data today, then well all I can say is lol
Patent law and science of HCV drugs are two separate tings FYI. You seem to be putting them in the same bracket for why, I'm not sure, but most likely because you are clueless on both.